Cargando…
BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer
In sporadic epithelial ovarian cancer (EOC), the inactivation of BRCA1 through various mechanisms is a relatively common event. BRCA1 protein dysfunction results in the breakdown of various critical pathways in the cell, notably, the DNA damage response and repair pathway. Tumors from patients with...
Autores principales: | Clark-Knowles, Katherine V., O'Brien, Anna M., Weberpals, Johanne I. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825770/ https://www.ncbi.nlm.nih.gov/pubmed/20182637 http://dx.doi.org/10.1155/2010/891059 |
Ejemplares similares
-
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
por: Weberpals, Johanne I, et al.
Publicado: (2011) -
Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011) -
The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer
por: McCoy, Marcia L, et al.
Publicado: (2003) -
Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases
por: Stavropoulou, Alexandra V., et al.
Publicado: (2013) -
The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)